Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

1.

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis.

Lalezari J, Latiff GH, Brinson C, Echevarria J, Treviño-Pérez S, Bogner JR, Stock D, Joshi SR, Hanna GJ, Lataillade M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19530. doi: 10.7448/IAS.17.4.19530. eCollection 2014.

PMID:
25394039
[PubMed - in process]
Free PMC Article
2.

Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH.

N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.

PMID:
25295501
[PubMed - indexed for MEDLINE]
3.

Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.

Timmins P, Brown J, Meanwell NA, Hanna GJ, Zhu L, Kadow JF.

Drug Discov Today. 2014 Sep;19(9):1288-93. doi: 10.1016/j.drudis.2014.03.025. Epub 2014 Apr 13.

PMID:
24727410
[PubMed - in process]
4.

Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.

Urata Y, Paintsil E, Cheng YC, Matsuda T, Sevinsky H, Hawthorne D, Bertz R, Hanna GJ, Grasela D, Hwang C.

J Clin Pharmacol. 2014 Jun;54(6):657-64. doi: 10.1002/jcph.252. Epub 2014 Jan 17.

PMID:
24374821
[PubMed - in process]
5.

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.

Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, Lataillade M, Hanna GJ, Krystal M.

J Antimicrob Chemother. 2014 Mar;69(3):573-81. doi: 10.1093/jac/dkt412. Epub 2013 Oct 14.

PMID:
24128669
[PubMed - in process]
6.

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Li Z, Terry B, Olds W, Protack T, Deminie C, Minassian B, Nowicka-Sans B, Sun Y, Dicker I, Hwang C, Lataillade M, Hanna GJ, Krystal M.

Antimicrob Agents Chemother. 2013 Nov;57(11):5500-8. doi: 10.1128/AAC.01195-13. Epub 2013 Aug 26.

PMID:
23979732
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.

Li Z, Zhou N, Sun Y, Ray N, Lataillade M, Hanna GJ, Krystal M.

Antimicrob Agents Chemother. 2013 Sep;57(9):4172-80. doi: 10.1128/AAC.00513-13. Epub 2013 Jun 17.

PMID:
23774428
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.

Cotte L, Dellamonica P, Raffi F, Yazdanpanah Y, Molina JM, Boué F, Urata Y, Chan HP, Zhu L, Chang I, Bertz R, Hanna GJ, Grasela DM, Hwang C.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):346-54. doi: 10.1097/QAI.0b013e3182965d12.

PMID:
23771104
[PubMed - indexed for MEDLINE]
9.

Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.

Ray N, Hwang C, Healy MD, Whitcomb J, Lataillade M, Wind-Rotolo M, Krystal M, Hanna GJ.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):7-15. doi: 10.1097/QAI.0b013e31829726f3.

PMID:
23614999
[PubMed - indexed for MEDLINE]
10.

Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?

Hanna GJ, Haddad RI, Lorch JH.

Oncologist. 2013;18(3):288-93. doi: 10.1634/theoncologist.2012-0286. Epub 2013 Feb 26. Review.

PMID:
23442306
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

Nettles RE, Schürmann D, Zhu L, Stonier M, Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, Hanna GJ, Bertz R, Grasela D.

J Infect Dis. 2012 Oct 1;206(7):1002-11. doi: 10.1093/infdis/jis432. Epub 2012 Aug 14.

PMID:
22896665
[PubMed - indexed for MEDLINE]
Free Article
12.

In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.

Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ, Matiskella JD, Ueda Y, Wang T, Kadow JF, Meanwell NA, Krystal M.

Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507. doi: 10.1128/AAC.00426-12. Epub 2012 Apr 30.

PMID:
22547625
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pathology quiz case 2. Solitary fibrous tumor (SFT) of the hypopharynx.

Hanna GJ, Grant N, Wycherly B.

Arch Otolaryngol Head Neck Surg. 2011 Aug;137(8):830; author reply 833-4. doi: 10.1001/archoto.2011.127-a. No abstract available.

PMID:
21844422
[PubMed - indexed for MEDLINE]
14.

Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.

Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, Krystal M, Lin P, Colonno R, Grasela DM.

Antimicrob Agents Chemother. 2011 Feb;55(2):722-8. doi: 10.1128/AAC.00759-10. Epub 2010 Nov 15.

PMID:
21078951
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.

Zhou N, Nowicka-Sans B, Zhang S, Fan L, Fang J, Fang H, Gong YF, Eggers B, Langley DR, Wang T, Kadow J, Grasela D, Hanna GJ, Alexander L, Colonno R, Krystal M, Lin PF.

Antimicrob Agents Chemother. 2011 Feb;55(2):729-37. doi: 10.1128/AAC.01173-10. Epub 2010 Nov 15.

PMID:
21078948
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.

Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ.

J Gen Intern Med. 2011 Mar;26(3):239-44. doi: 10.1007/s11606-010-1549-9. Epub 2010 Oct 27.

PMID:
20978862
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Measuring the volume of a fluid in a diamond anvil cell using a confocal microscope.

Hanna GJ, McCluskey MD.

Appl Opt. 2009 Mar 20;48(9):1758-63.

PMID:
19305474
[PubMed]
18.

"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.

Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ.

HIV Clin Trials. 2008 Jul-Aug;9(4):238-46. doi: 10.1310/hct0904-238.

PMID:
18753118
[PubMed - indexed for MEDLINE]
19.

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ.

J Infect Dis. 2008 Jul 15;198(2):234-40. doi: 10.1086/589622.

PMID:
18540803
[PubMed - indexed for MEDLINE]
Free Article
20.

Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

Klein CE, Chiu YL, Cai Y, Beck K, King KR, Causemaker SJ, Doan T, Esslinger HU, Podsadecki TJ, Hanna GJ.

J Clin Pharmacol. 2008 May;48(5):553-62. doi: 10.1177/0091270007313392.

PMID:
18440920
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk